JP2020530765A5 - - Google Patents

Info

Publication number
JP2020530765A5
JP2020530765A5 JP2020502118A JP2020502118A JP2020530765A5 JP 2020530765 A5 JP2020530765 A5 JP 2020530765A5 JP 2020502118 A JP2020502118 A JP 2020502118A JP 2020502118 A JP2020502118 A JP 2020502118A JP 2020530765 A5 JP2020530765 A5 JP 2020530765A5
Authority
JP
Japan
Prior art keywords
composition according
seq
composition
self
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020502118A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020530765A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2018/055258 external-priority patent/WO2019016680A1/en
Publication of JP2020530765A publication Critical patent/JP2020530765A/ja
Publication of JP2020530765A5 publication Critical patent/JP2020530765A5/ja
Pending legal-status Critical Current

Links

JP2020502118A 2017-07-17 2018-07-16 リサウイルス抗原構築物 Pending JP2020530765A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762533312P 2017-07-17 2017-07-17
US62/533,312 2017-07-17
PCT/IB2018/055258 WO2019016680A1 (en) 2017-07-17 2018-07-16 ANTIGEN CONSTRUCTS OF LYSSAVIRUS

Publications (2)

Publication Number Publication Date
JP2020530765A JP2020530765A (ja) 2020-10-29
JP2020530765A5 true JP2020530765A5 (enExample) 2022-05-25

Family

ID=63364109

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502118A Pending JP2020530765A (ja) 2017-07-17 2018-07-16 リサウイルス抗原構築物

Country Status (7)

Country Link
US (2) US11278613B2 (enExample)
EP (1) EP3655536A1 (enExample)
JP (1) JP2020530765A (enExample)
CN (1) CN111108203A (enExample)
BR (1) BR112020000802A2 (enExample)
CA (1) CA3070042A1 (enExample)
WO (1) WO2019016680A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110269933A (zh) * 2019-07-17 2019-09-24 苏州世诺生物技术有限公司 一种狂犬病毒亚单位疫苗的制备方法及其应用
CN110643632B (zh) * 2019-09-26 2022-06-10 中国科学院武汉病毒研究所 一种基于甲病毒复制子载体的狂犬病毒感染性克隆及制备方法和应用
WO2022077330A1 (zh) * 2020-10-15 2022-04-21 中国科学院深圳先进技术研究院 一种新型g基因及其在高效逆向跨单突触中的应用
CA3208643A1 (en) 2021-01-18 2022-07-21 Conserv Bioscience Limited Coronavirus immunogenic compositions, methods and uses thereof
CN113993839B (zh) * 2021-02-05 2024-02-09 嘉晨西海(杭州)生物技术有限公司 一种可离子化脂质分子、其制备方法及其在制备脂质纳米颗粒中的应用
WO2022244815A1 (ja) * 2021-05-19 2022-11-24 第一三共株式会社 Hpv感染症ワクチン
US20250137024A1 (en) 2021-09-01 2025-05-01 Glaxosmithkline Biologicals Sa Plasmid dna purification methods
CN117460827A (zh) * 2022-02-09 2024-01-26 苏州艾博生物科技有限公司 狂犬病核酸疫苗
CN116120198B (zh) * 2022-03-21 2024-03-15 苏州科锐迈德生物医药科技有限公司 具有甘油骨架的脂质化合物及基于其的脂质载体、核酸脂质纳米粒组合物和药物制剂
CN116063410B (zh) * 2022-10-20 2023-07-14 北京标驰泽惠生物科技有限公司 一种狂犬病毒g蛋白的突变体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101621100B1 (ko) * 2007-03-30 2016-05-13 더 리서치 파운데이션 오브 스테이트 유니버시티 오브 뉴욕 백신에 유용한 약독화 바이러스
BR112016001192A2 (pt) * 2013-08-21 2017-08-29 Curevac Ag Vacina contra a raiva
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
US10125092B2 (en) * 2014-09-05 2018-11-13 Novartis Ag Lipids and lipid compositions for the delivery of active agents
ES2959811T3 (es) 2016-12-09 2024-02-28 Glaxosmithkline Biologicals Sa Construcciones de adenovirus de chimpancé con antígenos de Lyssavirus
GB201620968D0 (en) * 2016-12-09 2017-01-25 Glaxosmithkline Biologicals Sa Adenovirus polynucleotides and polypeptides

Similar Documents

Publication Publication Date Title
JP2020530765A5 (enExample)
US11998597B2 (en) Vaccine against RSV
JP7523897B2 (ja) 呼吸器合胞体ウイルス(rsv)ワクチン
US20200069794A1 (en) Respiratory virus nucleic acid vaccines
EP4243789A1 (en) Compositions and methods for stabilization of lipid nanoparticle mrna vaccines
EP4226938A2 (en) Coronavirus vaccine
CN111526886A (zh) 多基因流感疫苗
JP2013523096A5 (enExample)
JP2024537250A (ja) インフルエンザワクチン
WO2023051701A1 (zh) 抗SARS-CoV-2感染的mRNA、蛋白以及抗SARS-CoV-2感染的疫苗
JP2025084850A (ja) ハンタウイルス抗原性組成物
CN109923125B (zh) 免疫原性组合物
CN120813371A (zh) 用于在衣原体病的治疗中使用的组合物
JP2025516330A (ja) 核酸ワクチンのシグナル配列
CN116650633A (zh) 冠状病毒疫苗
WO2025251934A1 (zh) 一种抗肝癌hla-a11型疫苗及其制备方法和应用
JP2026500282A (ja) インフルエンザウイルス様粒子をコードするmRNA
JP2023155245A5 (enExample)
EP3035960B1 (en) Respiratory syncytial virus (rsv) vaccine
US20250041400A1 (en) Rsv vaccine
HK40097472A (zh) 冠状病毒疫苗
WO2025251935A1 (zh) 一种抗肝癌hla-a02型疫苗及其制备方法和应用
WO2025260633A1 (zh) Rsv和hmpv融合f蛋白及其用途
WO2024100583A1 (en) Stabilized vaccines
JP2026065934A (ja) Snareを活用しウイルスに対する液性免疫を誘導する核酸構築物